welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!

Santhera’s Raxone® receives first positive EAMS scientific opinion from UK’s MHRA in Duchenne muscular dystrophy

The aim of the EAMS is to provide patients with life threatening or seriously debilitating conditions access to medicines that do not yet have a marketing authorization when there is a clear unmet medical need.1 The MHRA decision allows patients with DMD, who meet criteria defined under this scheme, to gain access to Raxone, an investigational medicinal product currently under review for DMD for Marketing Authorization by the European Medicines Agency (EMA).

Santhera’s Raxone® Receives First Positive EAMS Scientific Opinion From UK’s MHRA In Duchenne Muscular Dystrophy